On the other hand, there are some reports to show that overexpression of HER-2 is an independent prognostic factor of survival and to be a combinatorial target in lung cancer, using an EGFR tyrosine kinase inhibitor together with HER-2 dimerization inhibitors [12,13,21]. This evidence concerns the gene EGFR and lung carcinoma.